Asarina Pharma announced an administrative backlog due to Covid-19 at The Capil Region of Denmark (Region HoHovedstaden) is causing a delay of approx. 3 months to the initiation of the company's phase IIa study in Tourette Syndrome. The study is now expected to start in December 2021 and be completed at the end of 2022. The company's Clinical Trial Application for its phase IIa study in Tourette Syndrome was approved by the Danish Medical Agency in May 2021 and has now received approval from the Ethics Committee. The only outstanding matter is the contract with the two clinical sites, Herlev and Bispebjerg Hospitals. Due to a backlog in the legal department of Region Hovedstaden (the administrative authority for the two hospitals), the site contracts cannot be processed for approx. 2 months The Tourette study, scheduled to begin in September 2021 will consequently be delayed until December when it expects the site contracts to be signed. The study will be finalized at the end of 2022, not third quarter 2022 as previously communicated.